Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
Majority of pituitary tumours secrete one of the named hormones: PRL, GH, ACTH, proopiomelanocortine, alpha and beta subunit of TSH, LH, and FSH. Some of those tumours secrete two or more hormones. The aim of this study was to determine the effect of bromocriptine (Parlodel MR and LAR) upon secretion of hormones and tumour size in 10 patients with mixed pituitary tumours. In all patients pituitary and peripheral hormones, CT scan and visual fields were examined before and after treatment with bromocriptine: Parlodel MR and LAR. Bromocriptine treatment decreased PRL secretion in all 10 patients; GH--in all 6 in whom it was increased; TSH--in 2, FSH--in 2 and alpha-subunit in all 6 in whom they were increased. In 5 patients treatment resulted in shrinkage of the tumour mass by 20 to 35%. In all examined subjects clinical improvement was achieved. Our results demonstrate that bromocriptine (Parlodel MR and LAR) is very effective and well tolerated in the treatment of patients with mixed pituitary tumours particularly those with hyperprolactinemia.
Zgliczyński
W
W
Department of Endocrinology, Medical Center for Postgraduate Education, Warsaw.
Zgliczyński
S
S
Makowska
A
A
Słowinska-Srzednicka
J
J
Janik
J
J
Jeske
W
W
Walecki
J
J
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018198:Mixed Tumor, Malignant / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D010907:Pituitary Hormones / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D010907:Pituitary Hormones; D001971:Bromocriptine